Literature DB >> 7925987

Multi-step processing of procathepsin L in vitro.

K Ishidoh1, E Kominami.   

Abstract

The proteolytic processes involved in the conversion of procathepsin L to cathepsin L on a negatively charged surface, dextran sulfate, were studied. Upon incubation for 30 min at 37 degrees C, pH 5.5 with dextran-sulfate and dithiothreitol, purified procathepsin L showed maximal activation and, correspondingly, the complete conversion to the 30 kDa, single chain mature form of enzyme was observed. In contrast, incubation under the same conditions on ice rather than at 37 degrees C for 30 or 60 min resulted in partial proteolysis to produce a 31 kDa form without a significant increase in activity. Amino terminal amino acid sequence analyses showed that the 30 kDa form obtained by incubation at 37 degrees C corresponds to the purified form of mature cathepsin L with a 2 amino acid extension at the amino terminal, and that the 31 kDa form generated by incubation on ice possesses a 6 amino acid amino terminal extension, suggesting that the activation and processing of procathepsin L are different processes, and that 4 amino acid residues (Glu-Pro-Leu-Met) at the carboxyterminal in the propeptide function to prevent the activation of processed cathepsin L.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925987     DOI: 10.1016/0014-5793(94)00924-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

1.  Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease.

Authors:  Sanja Sever; Mehmet M Altintas; Sharif R Nankoe; Clemens C Möller; David Ko; Changli Wei; Joel Henderson; Elizabetta C del Re; Lianne Hsing; Ann Erickson; Clemens D Cohen; Matthias Kretzler; Dontscho Kerjaschki; Alexander Rudensky; Boris Nikolic; Jochen Reiser
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling.

Authors:  Desmond J Tobin; Kerstin Foitzik; Thomas Reinheckel; Lars Mecklenburg; Vladimir A Botchkarev; Christoph Peters; Ralf Paus
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

3.  CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival.

Authors:  Suma Yaddanapudi; Mehmet M Altintas; Andreas D Kistler; Isabel Fernandez; Clemens C Möller; Changli Wei; Vasil Peev; Jan B Flesche; Anna-Lena Forst; Jing Li; Jaakko Patrakka; Zhijie Xiao; Florian Grahammer; Mario Schiffer; Tobias Lohmüller; Thomas Reinheckel; Changkyu Gu; Tobias B Huber; Wenjun Ju; Markus Bitzer; Maria P Rastaldi; Phillip Ruiz; Karl Tryggvason; Andrey S Shaw; Christian Faul; Sanja Sever; Jochen Reiser
Journal:  J Clin Invest       Date:  2011-09-12       Impact factor: 14.808

4.  Cathepsin L acutely alters microvessel integrity within the neurovascular unit during focal cerebral ischemia.

Authors:  Yu-Huan Gu; Masato Kanazawa; Stephanie Y Hung; Xiaoyun Wang; Shunichi Fukuda; James A Koziol; Gregory J Del Zoppo
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-22       Impact factor: 6.200

5.  Recombinant Cathepsin L of Tribolium castaneum and Its Potential in the Hydrolysis of Immunogenic Gliadin Peptides.

Authors:  Elena A Dvoryakova; Maria A Klimova; Tatiana R Simonyan; Ivan A Dombrovsky; Marina V Serebryakova; Valeriia F Tereshchenkova; Yakov E Dunaevsky; Mikhail A Belozersky; Irina Y Filippova; Elena N Elpidina
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 6.  Optimizing dentin bond durability: control of collagen degradation by matrix metalloproteinases and cysteine cathepsins.

Authors:  Leo Tjäderhane; Fabio D Nascimento; Lorenzo Breschi; Annalisa Mazzoni; Ivarne L S Tersariol; Saulo Geraldeli; Arzu Tezvergil-Mutluay; Marcela R Carrilho; Ricardo M Carvalho; Franklin R Tay; David H Pashley
Journal:  Dent Mater       Date:  2012-08-16       Impact factor: 5.304

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.